Inobrodib
Cellcentric
['pioneer']
another strong day ahead at #esmo22. cellcentric in phase ii cancer trials with a pioneering p300/cbp inhibitor, both monotherapy and combination. 
Inobrodib (CCS1477): first-in-class p300/CBP small molecule inhibitor drug, to treat specific cancers.